Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C122H210N32O22.C2H4O2 |
Molecular Weight | 2537.226 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O
InChI
InChIKey=ZYMCXUWEZQKVIO-IJAHCEAPSA-N
InChI=1S/C122H210N32O22.C2H4O2/c1-13-77(9)102(152-98(155)71-132)120(174)135-73-100(157)139-86(50-26-35-59-125)110(164)150-96(69-82-44-20-16-21-45-82)118(172)148-93(66-74(3)4)116(170)145-90(54-30-39-63-129)113(167)142-87(51-27-36-60-126)109(163)137-79(11)105(159)141-88(52-28-37-61-127)112(166)143-91(55-31-40-64-130)114(168)149-95(68-81-42-18-15-19-43-81)107(161)134-72-99(156)138-85(49-25-34-58-124)108(162)136-80(12)106(160)147-97(70-83-46-22-17-23-47-83)119(173)153-101(76(7)8)121(175)146-92(56-32-41-65-131)115(169)154-103(78(10)14-2)122(176)151-94(67-75(5)6)117(171)144-89(53-29-38-62-128)111(165)140-84(104(133)158)48-24-33-57-123;1-2(3)4/h15-23,42-47,74-80,84-97,101-103H,13-14,24-41,48-73,123-132H2,1-12H3,(H2,133,158)(H,134,161)(H,135,174)(H,136,162)(H,137,163)(H,138,156)(H,139,157)(H,140,165)(H,141,159)(H,142,167)(H,143,166)(H,144,171)(H,145,170)(H,146,175)(H,147,160)(H,148,172)(H,149,168)(H,150,164)(H,151,176)(H,152,155)(H,153,173)(H,154,169);1H3,(H,3,4)/t77-,78-,79-,80-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,101-,102-,103-;/m0./s1
Pexiganan is a 22-amino-acid synthetic cationic peptide. It is an analog of magainin 2, which is a host defense peptide isolated from frog skin. The drug is thought to act by disturbing the permeability of the cell membrane or cell wall. Pexiganan exhibited in vitro broad-spectrum antibacterial activity when it was tested against 3,109 clinical isolates of gram-positive and gram-negative, anaerobic and aerobic bacteria. It is currently in phase 3 clinical trials as a topical antimicrobial agent for the treatment of mild infections associated with diabetic foot ulcers. In vitro data for pexiganan acetate suggest that the drug does have hemolytic activity at concentrations relevant for antibacterial activity. In association with tigecycline, pexiganan administration could overcome antibiotic resistance and increase the effectiveness of treatment against P. aeruginosa sepsis.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pexiganan acetate. | 1998 Dec |
|
In vitro antibacterial properties of pexiganan, an analog of magainin. | 1999 Apr |
|
In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. | 2015 Mar |
|
What Is the 'Minimum Inhibitory Concentration' (MIC) of Pexiganan Acting on Escherichia coli?-A Cautionary Case Study. | 2016 |
|
In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. | 2016 Sep |
|
In Vitro Activities of Pexiganan and 10 Comparator Antimicrobials against 502 Anaerobic Isolates Recovered from Skin and Skin Structure Infections. | 2017 Dec |
|
In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds. | 2017 Jun |
|
Efficacy of Pexiganan Combination with Tigecycline in a Mouse Model of Pseudomonas aeruginosa Sepsis. | 2018 |
|
Cost-effective downstream processing of recombinantly produced pexiganan peptide and its antimicrobial activity. | 2018 Jan 24 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9878992
1% cream (frequency of administration not stated)
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16137672
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | |||
|
C166896
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | |||
|
172820-23-4
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108556
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | |||
|
m8578
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
II-49
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY | |||
|
63S35FF5KS
Created by
admin on Sat Dec 16 00:43:55 GMT 2023 , Edited by admin on Sat Dec 16 00:43:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD